An API Innovation Center report highlighted four priorities to stabilize the U.S.-based supply of active pharmaceutical ingredients.
The report draws from roundtable discussions hosted at the nonprofit corporation in August, according to an Oct. 6 company news release. Leaders representing pharmaceutical manufacturing, hospital systems, retail pharmacies, government and the economic sector discussed what each needed to support a more reliable domestic supply chain. Currently, more than 250 medications are in shortage nationwide.
Here are the four priorities:
- Predictable demand and long-term contracts to de-risk private investment in U.S. manufacturing.
- A shift from lowest-cost purchasing to value-based models that reward reliability and quality.
- Greater transparency across the supply chain to enable smarter decisions and risk management.
- Broad stakeholder engagement to align incentives and ensure reliable access to critical medicines.
